• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences, Inc. - Common Stock (NQ:ENSC)

0.4580 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ensysce Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
September 24, 2026
~ Submission to the UK MHRA for review marks critical step towards initiating a Phase 2 Study with CY200 ~ 
From Ensysce Biosciences
Via ACCESS Newswire
News headline image
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
September 15, 2026
From Ensysce Biosciences
Via ACCESS Newswire
News headline image
Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
September 14, 2026
From Ensysce Biosciences
Via ACCESS Newswire
News headline image
Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
September 02, 2026
From Ensysce Biosciences
Via ACCESS Newswire
News headline image
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
June 26, 2026
From Ensysce Biosciences
Via ACCESS Newswire
News headline image
Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
August 31, 2026
From Ensysce Biosciences
Via ACCESS Newswire
News headline image
Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
August 20, 2026
From Ensysce Biosciences
Via ACCESS Newswire
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
August 14, 2026
Via Chartmill
News headline image
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 13, 2026
From Ensysce Biosciences
Via ACCESS Newswire
Top stock movements in today's session. ↗
August 06, 2026
Via Chartmill
Thursday's session: most active stocks ↗
August 06, 2026
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
August 06, 2026
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)... 
Via Benzinga
On Thursday, there are stocks with unusual volume. Let's take a look. ↗
August 06, 2026
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
August 06, 2026
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
August 06, 2026
Via Chartmill
Which stocks are moving before the opening bell on Thursday? ↗
August 06, 2026
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
August 06, 2026
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's pre-market session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)... 
Via Benzinga
News headline image
Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
August 06, 2026
From Ensysce Biosciences
Via ACCESS Newswire
News headline image
The Bull Lives Below $1: PRSO, ENSC, TNMG, QNME Stocks to Watch
August 04, 2026
Via AB Newswire
Topics Artificial Intelligence
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
August 04, 2026
Via Chartmill
These stocks are making the most noise in today's session. ↗
August 04, 2026
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
August 04, 2026
Via Chartmill
Tuesday's pre-market session: top gainers and losers ↗
August 04, 2026
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
August 04, 2026
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. Adagio Medical Holdings... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
August 03, 2026
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $3.8 million. TransCode Therapeutics... 
Via Benzinga
Stay updated with the stocks that are on the move in today's after-hours session. ↗
August 03, 2026
Via Chartmill
News headline image
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant
July 14, 2026
From Ensysce Biosciences
Via ACCESS Newswire
News headline image
Ensysce Biosciences Reports First Quarter 2026 Financial Results
May 15, 2026
Via ACCESS Newswire
News headline image
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
May 12, 2026
Via ACCESS Newswire
Check out the stocks that are attracting the most attention and driving market activity. ↗
May 11, 2026
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap